CureBRCA will consider funding BRCA-related initiatives that involve prevention, detection, screening, and/or treatment for men at risk for BRCA-related cancers. Applications are due by March 15, 2025. Interested parties are asked to submit an optional Notice of Intent (NOI).Read More…

The BRCA Research & Cure Alliance (CureBRCA) will be launching its 2025 Research Awards Program soon. Full information regarding types of applications being sought, eligibility, funding details, evaluation process, and the online application process will be posted here on November 1, 2024.Read More…

Published by: JAMA Oncology

This peer-reviewed article’s lead author is Heather Cheng, MD, PhD, with key contributions from Kara Maxwell, MD, PhD, Bryson Katona, MD, PhD, and Jeffrey Shevach, MD, along with a distinguished team of international experts.Read More…

People who test positive for BRCA1/2 genetic variants may be at risk for other types of cancer beyond those previously known, according to a study being presented at the National Society of Genetic Counselors (NSGC) 42nd Annual Conference.Read More…

In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalize treatments in the first-line as a study suggests.Read More…

In 2023, the BRCA Research & Cure Alliance (CureBRCA) initiated an open call for research applications resulting in $2.3 million distributed among five essential research endeavors. It is our hope that this research could be pivotal to understanding prostate cancer risk, prevention, and interception and bring hope to the multitude of BRCA gene mutation carriers.Read More…

The U.S. Food and Drug Administration (FDA) has approved 23andMe, which makes at-home genetic tests, to report the presence of 41 more variants, or mutations, of the BRCA1 and BRCA2 genes that are linked to a higher risk of developing breast, ovarian, prostate, and pancreatic cancers.Read More…

On August 11, 2023, the Food and Drug Administration approved the fixed dose combination of niraparib and abiraterone acetate (Akeega, Janssen Biotech, Inc.), with prednisone, for adult patients with deleterious or suspected (CONT)Read More…

On June 20, 2023, the Food and Drug Administration approved talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).Read More…